论文部分内容阅读
目的:比较头孢哌酮-舒巴坦与替加环素对肺癌患者化疗后肺部感染的临床疗效与安全性。方法:选取2015年3月—2016年3月间收治的肺癌化疗后肺部感染患者100例临床资料,将其随机分为对照组和观察组,每组50例;对照组患者给予替加环素治疗,观察组患者给予头孢哌酮-舒巴坦治疗,比较两组患者治疗后的总有效率和安全性以及血清内皮素(ET)、血管紧张素Ⅱ受体抗体(AngⅡ)和一氧化氮(NO)浓度的变化情况。结果:观察组患者治疗后的总有效率为84.00%高于对照组为62.00%(P<0.05),ET、AngⅡ和NO浓度的测得值优于对照组(P<0.05),不良反应的发生率与对照组比较其差异无统计学意义(P>0.05)。结论:采用头孢哌酮-舒巴坦治疗肺癌患者化疗后肺部感染的疗效优于替加环素。
Objective: To compare the clinical efficacy and safety of cefoperazone-sulbactam and tigecycline in patients with lung cancer after chemotherapy for lung cancer. Methods: The clinical data of 100 patients with pulmonary infection after lung cancer chemotherapy were collected from March 2015 to March 2016. They were randomly divided into control group and observation group, 50 cases in each group. Patients in the control group were given tigecycline The patients in the observation group were treated with cefoperazone-sulbactam. The total effective rate and safety after treatment were compared between the two groups. Serum levels of endothelin (ET), angiotensin II receptor (Ang II) and nitric oxide Nitrogen (NO) concentration changes. Results: The total effective rate of observation group after treatment was 84.00%, which was higher than that of control group (62.00%, P <0.05). The measured values of ET, Ang Ⅱ and NO were superior to those of control group (P0.05) There was no significant difference in incidence between the two groups (P> 0.05). CONCLUSIONS: Cefoperazone-sulbactam is superior to tigecycline in the treatment of lung infections in patients with lung cancer after chemotherapy.